CANGENE TO HOST FIRST QUARTER FISCAL 2011 CONFERENCE CALL ON WEDNESDAY,
DECEMBER 15, 2010 AT 11:00 A.M. EASTERN

Listed TSX, Symbol: CNJ

TORONTO AND WINNIPEG, Dec. 10 /CNW/ - Cangene Corporation today announces that it intends to host a conference call on Wednesday, December 15, 2010 at 11:00 a.m. Eastern to discuss its financial results for the first quarter of fiscal 2011, ended October 31, 2010.  The Company intends to disclose its financial results via news release after market close on Tuesday, December 14, 2010.

To access the conference call by telephone, dial 647-427-7450 or 1-888-231-8191.  The conference call will be archived for replay until Wednesday, December 22, 2010, at midnight. To access the archived conference call, dial 416-849-0833 or 1-800-642-1687 and enter the reservation number 31119772 followed by the number sign.

A live audio webcast of the conference call will be available at www.cangene.com and www.newswire.ca.  Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast.  The webcast will be archived at the above web sites for 90 days.

About Cangene Corporation
Cangene is one of Canada's largest and earliest biopharmaceutical companies.  It was founded in 1984 and is headquartered in Winnipeg, Manitoba.  Cangene has approximately 800 employees in six locations across North America and its products are sold worldwide.  It operates manufacturing facilities in Winnipeg, Manitoba and Baltimore, Maryland where it produces its own products and undertakes contract manufacturing for a number of companies.  Cangene operates three U.S. and one Canadian plasma-collection facilities branded as Cangene Plasma Resources (www.cangeneplasma.com).  In addition, it has a regulatory affairs, sales and corporate communications office in Toronto, Ontario.

Cangene is focused on developing therapeutics for infectious diseases, and the Company uses patented manufacturing processes to produce plasma-derived and recombinant therapeutic proteins. Cangene has four FDA and/or Health Canada-approved hyperimmune products.  In addition, the Company has several more products in development at various stages.  Three of Cangene's products have been accepted into the U.S. Strategic National Stockpile—botulism antitoxin (investigational product), anthrax immune globulin (investigational product) and a vaccinia immune globulin, a product that may be used to counteract certain complications that may arise from smallpox vaccination.  Capitalizing on its drug manufacturing expertise, Cangene also operates a significant contract research and manufacturing business using the resources of Baltimore, Maryland-based Cangene bioPharma, Inc. (a wholly owned subsidiary; formerly Chesapeake Biological Laboratories, Inc.; www.cangenebiopharma.com).  Cangene's website, www.cangene.com, includes product and investor information, including past news releases.

For further information:

about Cangene Corporation, please contact Jean Compton at [phone] or by email at [email protected]